Table 4.
Univariable and multivariable analyses of the association between clinical and laboratory variables and death
| Total n for analysis | Univariable Analysis HR (95%CI) |
P | Multivariable Analysis HR (95%CI) |
P* | |
|---|---|---|---|---|---|
| Age | 147 | 1.079 (1.027–1.134) | 0.003 | ||
| Type | 147 | ||||
| Severe | 42 | 2.896 (1.473–5.692) | 0.002 | 2.983 (1.231–7.226) | 0.016 |
| Critical | 16 | 3.542 (1.515–8.284) | 0.004 | 3.267 (1.009–10.576) | 0.048 |
| Leukocytes (109/L) | 147 | ||||
| < 3.5 | 13 | 3.153 (1.251–7.948) | 0.015 | ||
| > 9.5 | 32 | 3.931 (2.043–7.563) | < 0.001 | ||
| Lymphocytes (109/L) | 147 | ||||
| < 1.1 | 100 | 2.656 (1.179–5.983) | 0.018 | ||
| Neutrophils (109/L) | 147 | ||||
| < 1.8 | 9 | 1.289 (0.296–5.611) | 0.735 | ||
| > 6.3 | 48 | 3.366 (1.786–6.344) | 0.001 | ||
| AST (U/L) | 147 | ||||
| < 15 | 4 | 1.180 (0.158–8.831) | 0.872 | ||
| > 40 | 50 | 2.523 (1.365–4.664) | 0.003 | ||
| CK (U/L) | 147 | ||||
| < 50 | 50 | 0.814 (0.395–1.680) | 0.578 | ||
| > 310 | 15 | 2.990 (1.373–6.511) | 0.006 | ||
| Creatinine (μmol/L) | 147 | ||||
| < 57 | 37 | 1.527 (0.715–3.261) | 0.274 | ||
| > 111 | 23 | 3.987 (1.961–8.103) | 0.001 | ||
| BUN (mmol/L) | 147 | ||||
| < 3.6 | 7 | 1.623 (0.378–6.969) | 0.515 | 3.812 (0.788–18.435) | 0.096 |
| > 9.5 | 37 | 3.913 (2.099–7.291) | < 0.001 | 2.805 (1.141–6.892) | 0.025 |
| Globulin (g/L) | 147 | ||||
| < 20 | 12 | 0.263 (0.036–1.915) | 0.187 | ||
| > 40 | 3 | 2.042 (0.493–8.468) | 0.325 | ||
| Dyspnea | 147 | 1.641 (0.895–3.007) | 0.109 | ||
| Hormone therapy | 147 | 2.393 (1.260–4.547) | 0.008 | ||
| Antiviral therapy | 147 | 0.188 (0.057–0.615) | 0.006 | ||
| Oxygen therapy | 147 | 4.154 (0.571–30.210) | 0.160 | ||
| Vasoactive drugs | 147 | 14.126 (7.238–27.569) | < 0.001 | 16.120 (6.573–39.533) | < 0.001 |
| LDH (U/L) | 147 | ||||
| > 250 | 98 | 5.221 (1.862–14.639) | 0.002 | ||
| Procalcitonin (ng/mL) | 137 | ||||
| > 0.1 | 64 | 2.715 (1.405–5.244) | 0.003 | ||
| CD3 (/μL) | 122 | ||||
| < 723 | 93 | 9.718 (1.325–71.263) | 0.025 | ||
| CD4 (/μL) | 122 | ||||
| < 404 | 95 | 6.496 (1.550–27.232) | 0.011 | ||
| CD8 (/μL) | 122 | ||||
| < 220 | 85 | 3.089 (1.081–8.829) | 0.035 | ||
| CD19 (/μL) | 122 | ||||
| < 80 | 43 | 1.975 (0.976–3.995) | 0.058 | ||
| CD16 + CD56 (/μL) | 122 | ||||
| < 84 | 49 | 2.516 (1.221–5.186) | 0.012 | ||
| IgA (g/L) | 121 | ||||
| > 4.0 | 19 | 1.012 (0.388–2.635) | 0.981 | ||
| IgM (g/L) | 121 | ||||
| < 0.4 | 14 | 0.946 (0.286–3.126) | 0.927 | ||
| > 2.3 | 3 | 2.416 (0.573–10.184) | 0.230 | ||
| IgE (IU/mL) | 121 | ||||
| > 100 | 30 | 1.541 (0.725–3.272) | 0.261 |
*A forward and backward stepwise selection with P values of 0.10 for the forward procedure and 0.05 for the backward procedure was used to select the variables for the final model. AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; IgM, immunoglobulin M; IgA, immunoglobulin A; IgE, immunoglobulin E; CD, cluster of differentiation. *P < 0.05